Clinical Trial Update: Vortioxetine for Post-COVID-19 Condition [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating vortioxetine for Post-COVID-19 condition has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Post-covid-19 Condition

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: Brain and Cognition Discovery Foundation | Conditions: Post-COVID-19 Condition, Post-COVID-19 Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-01-16